1. Essential Updates for PsA: A Complex Disease to Manage

3. Program Overview

4. PsA: Highly Heterogeneous Disease

5. Epidemiology of PsA

6. Pathogenesis of PsA

7. Immunopathogenesis of PsA

8. Main Players in IL-23/IL-17 Axis: Roles in Psoriasis and PsA

9. PsA: Importance of Early Diagnosis

10. Delayed Diagnosis of PsA Is Associated With Worse Long-Term Outcomes

11. Multidisciplinary Management of Patients With PsA

12. PsA Management: Bridging Rheumatology and Dermatology

13. PsA Treatment

14. PsA Principles of Treatment

15. Patient Concerns Are Important

16. The Psychosocial Burden of PsA

17. Outcome Measures in PsA*

18. Using Outcome Measures in the Management of Patients With PsA

19. Treat-To-Target

20. Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA

21. TICOPA: ACR20 Response at 48 Weeks

22. TICOPA: Commonly Reported AEs

23. MDA Criteria for PsA

24. Targeted Agents for the Treatment of PsA

25. Novel Targeted Therapies for the Treatment of PsA

26. IL-17 Isoforms, Their Receptors, and Key Molecules Involved in Signal Transduction

27. Treatment With IL-17 Inhibitors in Patients With PsA

28. Ixekizumab Improves PROs in bDMARD-Naive Patients With PsA: Results From SPIRIT-P1

29. Bimekizumab in PsA: Results From BE ACTIVE Phase 2b Study

30. Safety Profile of IL-17 Inhibitors in PsA

31. Use of IL-17 Inhibitors in Clinical Practice

32. The Psychosocial Burden of PsA and the Importance of PROs

33. Program Summary

34. Program Summary (cont)

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)

38. Abbreviations (cont)